Literature DB >> 19757047

Expression of VEGF, EGFR, and IL-6 in gastric adenomas and adenocarcinomas by endoscopic submucosal dissection.

Shin-Ae Lee1, Seok-Reyol Choi, Jin-Seok Jang, Jong-Hun Lee, Myung-Hwan Roh, Sang Ock Kim, Min-Chan Kim, Su-Jin Kim, Jin-Sook Jeong.   

Abstract

BACKGROUND: The degree of intratumoral microvascular density is thought to affect tumor metastasis and prognosis in various human cancers, including gastric cancer. Despite recent medical advancements, gastric adenoma or adenocarcinoma remains a considerable therapeutic challenge. Endoscopic submucosal dissection (ESD) is a more recent approach that is now commonly used for radical resection of gastric adenoma and adenocarcinoma. AIM AND METHODS: The expression of vascular endothelial growth factor (VEGF), epidermal growth factor receptor (EGFR), and interleukin-6 (IL-6) are related to the prognosis of gastric adenocarcinoma. However, the expression of these factors in gastric adenoma/adenocarcinoma following ESD has not been clearly evaluated. Here, we report on our study of the expression of VEGF, EGFR, and IL-6 by immunohistochemical staining in extracted tissue from adenoma or adenocarcinoma of the stomach by ESD and subsequent evaluation of the correlation of VEGF, EGFR, and IL-6 with other clinicopathological parameters. The patient cohort consisted of 102 patients with adenoma or adenocarcinoma of the stomach.
RESULTS: Immunohistochemical staining for VEGF and IL-6 was significantly higher in both high grade dysplasia and adenocarcinoma than in low grade dysplasia (P < 0.05). There was significant correlation between histological grade and intensity of immunohistochemical staining of VEGF (P = 0.039). Histological differentiation of adenocarcinoma was related to IL-6 expression (P = 0.028). The immunoreactivity of VEGF and IL-6 increased significantly in lesions >2 cm compared to lesions <2 cm (P < 0.05).
CONCLUSION: The immunohistochemical expression of IL-6 and VEGF can be considered to be useful for clinical diagnosis and follow-up of adenoma or adenocarcinoma of the stomach.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19757047     DOI: 10.1007/s10620-009-0967-1

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  40 in total

1.  Immunohistochemical localization of interleukin-6 and its receptor in benign, premalignant and malignant prostate tissue.

Authors:  A Hobisch; H Rogatsch; A Hittmair; D Fuchs; G Bartsch; H Klocker; G Bartsch; Z Culig
Journal:  J Pathol       Date:  2000-07       Impact factor: 7.996

2.  Comparative study of tumor angiogenesis and immunohistochemistry for p53, c-ErbB2, c-myc and EGFr as prognostic factors in gastric cancer.

Authors:  J Sanz-Ortega; S M Steinberg; E Moro; M Saez; J A Lopez; E Sierra; J Sanz-Esponera; M J Merino
Journal:  Histol Histopathol       Date:  2000-04       Impact factor: 2.303

3.  Intratumoral neovascularization and growth pattern in early gastric carcinoma.

Authors:  M Tomoda; Y Maehara; Y Kakeji; S Ohno; Y Ichiyoshi; K Sugimachi
Journal:  Cancer       Date:  1999-06-01       Impact factor: 6.860

4.  Correlation between serum levels of interleukin-6 and vascular endothelial growth factor in gastric carcinoma.

Authors:  Shih-Pei Huang; Ming-Shiang Wu; Hsiu-Po Wang; Chang-Shiu Yang; Min-Liang Kuo; Jaw-Town Lin
Journal:  J Gastroenterol Hepatol       Date:  2002-11       Impact factor: 4.029

5.  Purification and NH2-terminal amino acid sequence of guinea pig tumor-secreted vascular permeability factor.

Authors:  D R Senger; D T Connolly; L Van de Water; J Feder; H F Dvorak
Journal:  Cancer Res       Date:  1990-03-15       Impact factor: 12.701

6.  Expression of Cbl linking with the epidermal growth factor receptor system is associated with tumor progression and poor prognosis of human gastric carcinoma.

Authors:  Reiko Ito; Hirofumi Nakayama; Kazuhiro Yoshida; Shunji Matsumura; Noriko Oda; Wataru Yasui
Journal:  Virchows Arch       Date:  2004-02-26       Impact factor: 4.064

7.  Inhibition of heat shock protein 90 impairs epidermal growth factor-mediated signaling in gastric cancer cells and reduces tumor growth and vascularization in vivo.

Authors:  Sven A Lang; Dagmar Klein; Christian Moser; Andreas Gaumann; Gabriel Glockzin; Marc H Dahlke; Wolfgang Dietmaier; Ulrich Bolder; Hans J Schlitt; Edward K Geissler; Oliver Stoeltzing
Journal:  Mol Cancer Ther       Date:  2007-03       Impact factor: 6.261

8.  Epidermal growth factor receptor (EGFR) expression is associated with a worse prognosis in gastric cancer patients undergoing curative surgery.

Authors:  Gennaro Galizia; Eva Lieto; Michele Orditura; Paolo Castellano; Anna La Mura; Vincenzo Imperatore; Margherita Pinto; Anna Zamboli; Ferdinando De Vita; Francesca Ferraraccio
Journal:  World J Surg       Date:  2007-07       Impact factor: 3.352

9.  Interleukin-6 increases vascular endothelial growth factor and angiogenesis in gastric carcinoma.

Authors:  Shih-Pei Huang; Ming-Shiang Wu; Chia-Tung Shun; Hsiu-Po Wang; Ming-Tsan Lin; Min-Liang Kuo; Jaw-Town Lin
Journal:  J Biomed Sci       Date:  2004 Jul-Aug       Impact factor: 8.410

10.  p53 and VEGF expression are independent predictors of tumour recurrence and survival following curative resection of gastric cancer.

Authors:  C Fondevila; J P Metges; J Fuster; J J Grau; A Palacín; A Castells; A Volant; M Pera
Journal:  Br J Cancer       Date:  2004-01-12       Impact factor: 7.640

View more
  9 in total

1.  Prognostic significance of vascular endothelial growth factor expression in gastric carcinoma: a meta-analysis.

Authors:  Jing Chen; Tao Li; Yuanyuan Wu; Lijun He; Li Zhang; Tieliu Shi; Zhengfang Yi; Mingyao Liu; Xiufeng Pang
Journal:  J Cancer Res Clin Oncol       Date:  2011-09-15       Impact factor: 4.553

2.  Piperine inhibits IL-1β-induced IL-6 expression by suppressing p38 MAPK and STAT3 activation in gastric cancer cells.

Authors:  Yong Xia; Pham Ngoc Khoi; Hyun Joong Yoon; Sen Lian; Young Eun Joo; Kee Oh Chay; Kyung Keun Kim; Young Do Jung
Journal:  Mol Cell Biochem       Date:  2014-09-19       Impact factor: 3.396

3.  Aberrant expression of EphA3 in gastric carcinoma: correlation with tumor angiogenesis and survival.

Authors:  Hong-Qing Xi; Xiao-Song Wu; Bo Wei; Lin Chen
Journal:  J Gastroenterol       Date:  2012-02-17       Impact factor: 7.527

4.  Comparison between clinical significance of serum proinflammatory proteins (IL-6 and CRP) and classic tumor markers (CEA and CA 19-9) in gastric cancer.

Authors:  Marta Lukaszewicz-Zając; Barbara Mroczko; Mariusz Gryko; Bogusław Kędra; Maciej Szmitkowski
Journal:  Clin Exp Med       Date:  2010-10-12       Impact factor: 3.984

5.  Acceleration of gastric tumorigenesis through MKRN1-mediated posttranslational regulation of p14ARF.

Authors:  Aram Ko; Ji-Young Shin; Jinho Seo; Kang-Duck Lee; Eun-Woo Lee; Min-Sik Lee; Han-Woong Lee; Il-Ju Choi; Jin Sook Jeong; Kyung-Hee Chun; Jaewhan Song
Journal:  J Natl Cancer Inst       Date:  2012-10-25       Impact factor: 13.506

6.  Interleukin-6 mediates epithelial-stromal interactions and promotes gastric tumorigenesis.

Authors:  Hiroto Kinoshita; Yoshihiro Hirata; Hayato Nakagawa; Kei Sakamoto; Yoku Hayakawa; Ryota Takahashi; Wachiko Nakata; Kosuke Sakitani; Takako Serizawa; Yohko Hikiba; Masao Akanuma; Wataru Shibata; Shin Maeda; Kazuhiko Koike
Journal:  PLoS One       Date:  2013-04-12       Impact factor: 3.240

7.  Signal transducer and activator of transcription 3 signaling upregulates fascin via nuclear factor-κB in gastric cancer: Implications in cell invasion and migration.

Authors:  Jun Yao; Cui-Juan Qian; Bei Ye; Zhi-Qiang Zhao; Jie Wei; Yong Liang; Xin Zhang
Journal:  Oncol Lett       Date:  2014-01-15       Impact factor: 2.967

8.  Ablation of galectin-3 induces p27(KIP1)-dependent premature senescence without oncogenic stress.

Authors:  S-J Kim; H-W Lee; H Gu Kang; S-H La; Il Ju Choi; J Y Ro; R S Bresalier; J Song; K-H Chun
Journal:  Cell Death Differ       Date:  2014-06-27       Impact factor: 15.828

Review 9.  Systematic literature review of IL-6 as a biomarker or treatment target in patients with gastric, bile duct, pancreatic and colorectal cancer.

Authors:  Noomi Vainer; Christian Dehlendorff; Julia S Johansen
Journal:  Oncotarget       Date:  2018-07-03
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.